Blocking HIV-1 Replication by Targeting the Tat-Hijacked Transcriptional Machinery

Author(s): Serena Massari, Stefano Sabatini, Oriana Tabarrini

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 10 , 2013

Become EABM
Become Reviewer
Call for Editor


HIV-1 infection can be effectively controlled by HAART, which improves the quality of lives of infected individuals, but fails to completely eradicate the virus, even after decades of treatment. This issue, together with the emergence of multi-drug-resistant viruses, clearly underscores the continuing need to find novel agents able to target vulnerable steps in the viral replication cycle. HIV transcriptional regulation is a crucial step required to re-initiate viral replication from post-integration latency after interruption of therapy and to keep the virus in circulation. In this step, the viral protein Tat plays a central role by dramatically increasing the production of elongated transcripts through its unique interaction with the viral TAR RNA and the cellular cofactor P-TEFb, together with a myriad of other host factors which are recruited to the viral promoter to ensure efficient transcription. The transcriptional machinery, involving an intricate interplay of many viral and cellular components, offers a plethora of potential therapeutic targets that have not yet been exploited by any of the antiretroviral drugs used in therapy.

In this review we explore the state-of-the-art of Tat-mediated transcription inhibitors which target the well-consolidated Tat/TAR/PTEFb axis, together with novel therapeutics that interfere with various host-cell factors, including some pioneer inhibitors designed on the basis of recent molecular and structural studies.

Keywords: HIV-1, Tat, TAR, P-TEFb, transactivation, latency, transcription inhibitors, small molecules

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [1860 - 1879]
Pages: 20
DOI: 10.2174/1381612811319100010
Price: $65

Article Metrics

PDF: 49